FDA panel takes up BPC-157 as compounding evidence comes under review

What happened

The FDA’s Pharmacy Compounding Advisory Committee opened a two-day meeting with BPC-157-related bulk drug substances on the agenda. The agency’s briefing package evaluated the free-base and acetate forms separately and examined characterization, historical use, effectiveness, safety and proposed compounded dosage forms.

What the record says

FDA staff wrote that the available criteria weighed against placing either form on the section 503A bulks list. The document also stressed inconsistent naming, limited clinical evidence for nominated uses and peptide-quality questions that can affect identity, stability and impurities.

What it does not mean

An advisory committee meeting is part of the regulatory process, not an approval. Committee recommendations are non-binding, and FDA said its final determination would come only after the advisory process and full review.

Why it matters

The record directly challenges the gap between BPC-157’s online reputation and the evidence needed for a compounded drug ingredient. The central issue is not popularity; it is whether the specific substance can be characterized and supported for the proposed use.